IRIS
CANONICA, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.393
AS - Asia 15.240
EU - Europa 7.487
SA - Sud America 6.182
AF - Africa 994
Continente sconosciuto - Info sul continente non disponibili 960
OC - Oceania 38
AN - Antartide 1
Totale 54.295
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.632
SG - Singapore 8.633
BR - Brasile 4.982
IT - Italia 3.168
VN - Vietnam 2.517
CN - Cina 2.050
FI - Finlandia 975
IE - Irlanda 843
NG - Nigeria 601
DE - Germania 551
AR - Argentina 502
FR - Francia 472
CA - Canada 398
GB - Regno Unito 385
NL - Olanda 312
IN - India 287
HK - Hong Kong 268
TR - Turchia 244
BD - Bangladesh 234
EC - Ecuador 226
ID - Indonesia 216
RU - Federazione Russa 206
MX - Messico 179
CO - Colombia 134
IQ - Iraq 129
ZA - Sudafrica 126
SE - Svezia 122
UA - Ucraina 96
IL - Israele 94
PY - Paraguay 93
PK - Pakistan 77
CL - Cile 74
VE - Venezuela 70
PL - Polonia 63
SA - Arabia Saudita 61
UZ - Uzbekistan 56
ES - Italia 55
EG - Egitto 47
MA - Marocco 46
KE - Kenya 44
UY - Uruguay 42
TN - Tunisia 40
JP - Giappone 38
PE - Perù 35
DZ - Algeria 31
JM - Giamaica 31
AU - Australia 29
BE - Belgio 29
KR - Corea 27
NP - Nepal 27
PH - Filippine 27
AZ - Azerbaigian 24
JO - Giordania 24
DO - Repubblica Dominicana 23
RO - Romania 23
AE - Emirati Arabi Uniti 22
BO - Bolivia 21
CZ - Repubblica Ceca 21
IR - Iran 20
KZ - Kazakistan 20
AT - Austria 19
CR - Costa Rica 18
ET - Etiopia 18
TT - Trinidad e Tobago 18
AL - Albania 17
MY - Malesia 17
HN - Honduras 16
OM - Oman 15
BG - Bulgaria 14
KG - Kirghizistan 14
PA - Panama 14
SV - El Salvador 14
GR - Grecia 13
LT - Lituania 13
GT - Guatemala 12
PT - Portogallo 12
PR - Porto Rico 11
SN - Senegal 11
SY - Repubblica araba siriana 11
LB - Libano 10
AM - Armenia 9
GE - Georgia 9
MN - Mongolia 9
NI - Nicaragua 9
PS - Palestinian Territory 9
A2 - ???statistics.table.value.countryCode.A2??? 8
BA - Bosnia-Erzegovina 8
CH - Svizzera 8
KW - Kuwait 8
RS - Serbia 8
BH - Bahrain 7
MD - Moldavia 7
AO - Angola 6
BB - Barbados 6
DK - Danimarca 6
HR - Croazia 6
LV - Lettonia 6
TH - Thailandia 6
TW - Taiwan 6
BW - Botswana 5
Totale 53.255
Salva come PNG Salva come JPEG
Città #
Wilmington 4.533
Singapore 3.406
San Mateo 1.696
The Dalles 1.555
Milan 1.365
Dallas 1.156
Ashburn 1.092
Ann Arbor 1.032
Shanghai 1.010
Helsinki 972
Ho Chi Minh City 925
Leawood 866
Dublin 837
Council Bluffs 824
Princeton 785
Lawrence 775
Rome 637
Benin City 594
Fairfield 583
Hanoi 524
Woodbridge 516
Chandler 488
San Jose 423
São Paulo 415
Paris 403
Beijing 329
New York 284
Amsterdam 271
Los Angeles 254
Hong Kong 250
Santa Clara 249
London 195
Toronto 183
Kocaeli 168
Orem 155
Rio de Janeiro 145
Falkenstein 141
Boardman 112
Figino 106
Haiphong 105
Norwalk 101
Bradenton 96
Buffalo 96
Turin 96
Da Nang 94
Phoenix 94
Brasília 88
Curitiba 88
Guayaquil 87
Belo Horizonte 84
Naples 77
Chicago 75
Porto Alegre 75
Chennai 69
Campinas 66
Biên Hòa 65
Montreal 65
Guarulhos 62
Dhaka 58
Manchester 57
Quito 56
Philadelphia 54
Houston 53
Salvador 52
Tashkent 51
Warsaw 51
Mansfield 48
Charlotte 47
Johannesburg 47
Ellicott City 46
Seattle 46
Buenos Aires 45
Hải Dương 44
Asunción 43
Monmouth Junction 43
Moscow 43
Brooklyn 41
Jakarta 41
Mumbai 41
Bologna 40
Florence 39
Frankfurt am Main 39
Ninh Bình 39
Atlanta 38
Montevideo 38
Ribeirão Preto 37
Baghdad 36
Mexico City 35
Nairobi 35
Sorocaba 35
Altamonte Springs 34
Fortaleza 34
Goiânia 34
Miami 34
Thái Bình 34
Cincinnati 33
São Bernardo do Campo 33
Birmingham 32
Can Tho 32
Thái Nguyên 32
Totale 33.587
Salva come PNG Salva come JPEG
Nome #
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco 752
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis 287
Quality of life and polysensitization in young men with intermittent asthma 218
A critical appraisal on AIT in childhood asthma. 158
Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab 137
Effects on symptoms and quality of life of hypertonic saline nasal spray added to antihistamine in persistent allergic rhinitis--a randomized controlled study 137
Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients. 134
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry 132
Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study 126
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. 120
An academic allergy unit during COVID-19 pandemic in Italy. 119
Pidotimod: The state of art 113
A Charter to Improve Patient Care in Severe Asthma 111
Work productivity in rhinitis using cell phones: The MASK pilot study 111
The Severe Asthma Network in Italy: Findings and Perspectives 109
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy 109
Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps 108
360 degree perspective on allergic rhinitis management in Italy: A survey of GPs, pharmacists and patients 107
Treatable traits in chronic rhinosinusitis with nasal polyps 107
A multi-allergen ELISA screening method. Comparison with Pharmacia CAP system and Phazet skin prick test 106
30 Years Of Sublingual Immunotherapy 106
Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing 105
A 4-year trial of tiotropium in chronic obstructive pulmonary disease 105
60Co therapy as an "allergic breakthrough" in a case of food allergy 105
2019 ARIA Care pathways for allergen immunotherapy 104
Comparison of the colony forming capacities of human T lymphocyte subpopulations 102
Pitfalls in respiratory allergy management: alexithymia and its impact on patient-reported outcomes 97
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 96
Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA) 96
A model of allergen-driven human airway contraction:beta2 pathway dysfunction without cytokine involvement 96
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe 95
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) 94
A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress 93
[GA(2)LEN (Global Allergy and Asthma European Network): European network of excellence for asthma and allergic diseases] 93
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 93
Strategies to reduce corticosteroid-related adverse events in asthma 92
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects 92
Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study 91
Clinical Characteristics Associated with Conjunctival Inflammation in Allergic Rhinoconjunctivitis 91
IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper 91
The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU 91
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 90
Pharmacoeconomic evaluation of oral corticosteroid adverse events in patients with severe asthma 90
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice 90
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis 89
New drugs in early-stage clinical trials for allergic rhinitis 88
A multicentric study on sensitivity and specificity of a new in vitro test for measurement of IgE antibodies 88
Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma 88
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria 88
Microarray Immunodiagnostics for Aeroallergens 87
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL) 87
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 87
Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study 87
Appropriateness in allergic respiratory diseases health care in Italy: definitions and organizational aspects 86
International consensus on allergy immunotherapy 86
Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients 86
Role of leukotrienes receptors antagonista in the management of mild-to-moderate asthma 86
Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva allergen challenge 86
[Our experience in the treatment of bronchial asthma and asthmatic bronchitis with salbutamol] 86
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials 86
EAACI guidelines on allergen immunotherapy: Executive statement 85
Meta analysis of SLIT in children 85
Do Asthmatic Patients and Their Physicians Agree on the Presence and Severity of Allergic Rhinitis? 85
EAACI/GA2LEN/EDF guideline: management of urticaria 85
Cross-Country Comparison of Demographic and Clinical Characteristics of Patients Managed in Severe Asthma Services Across UK, USA, Australia, South Korea, and Italy 85
World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics 84
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma 84
Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions 84
Sublingual immunotherapy: update 2006 84
Cytokines and airways: recent insights and therapeutic implications 84
Escaping the trap of allergic rhinitis. 83
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy 83
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update 83
Assessing biomarkers in a real-world severe asthma study (ARIETTA) 83
BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma 83
[ICAM-1 and allergic inflammation] 83
Umeclidinium for the treatment of uncontrolled asthma 83
A survey of the burden of allergic rhinitis in Europe 83
Allergen Immunotherapy (AIT): A prototype of Precision Medicine 82
The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial 82
Patient-reported outcomes in asthma clinical trials 82
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 81
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma 81
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters 81
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision 81
Characteristics of patients with seasonal allergic rhinitis and concomitant asthma 81
Adherence to asthma treatments: 'We know, we intend, we advocate' 81
The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes 81
Cetirizine treatment of allergic cough in children with pollen allergy 81
The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners 81
The relationship between allergen immunotherapy and omalizumab for treating asthma 80
Efficacy and Safety of High ICS Dose Fixed-Combination ICS/LABA/LAMA pMDI Compared with ICS/LABA and ICS/LABA plus LAMA in Patients with Uncontrolled Asthma: The TRIGGER Study 80
Seasonal and perennial allergic rhinitis: is this classification adherent to real life? 80
[Anti-leukotriene agents: rationale for and prospects of use] 80
Fatal asthma; is it still an epidemic? 80
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis 80
General strategy for the management of bronchial asthma in pregnancy 80
Quality-of-life issues in survivors to anaphylactic reactions to drugs 80
New insights in allergen avoidance measures for mite and pet sensitized patients. A critical appraisal 80
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs 79
Totale 10.273
Salva come PNG Salva come JPEG
Categoria #
all - tutte 373.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 373.280
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.946 0 0 50 781 15 17 130 610 304 295 680 64
2022/20234.261 1.617 85 825 139 101 86 19 93 282 774 218 22
2023/20243.395 168 387 769 31 32 141 119 116 50 34 638 910
2024/20255.980 79 34 38 53 56 786 211 381 704 1.955 748 935
2025/202624.138 2.647 1.455 2.593 5.006 661 506 3.665 1.334 1.353 1.101 650 3.167
2026/20274.501 3.298 1.188 15 0 0 0 0 0 0 0 0 0
Totale 54.295